Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The FDA Amendments Act-A Year On

This article was originally published in SRA

Executive Summary

The US Food and Drug Administration Amendments Act of 2007 came into force just over a year ago and contained important ramifications for manufacturers of medical devices and in vitro diagnostics. Neena Brizmohun reports from the annual meeting of the Regulatory Affairs Professionals Society, in Boston, on how the act is faring.

You may also be interested in...



FDA Conflict Of Interest Waiver On Victoza Is Textbook Example For Supporters, Foes

Novo Nordisk's Victoza will get US advisory committee review June 20, and Tufts Medical Center's Marvin Konstam will serve on panel even though his institution participates in a trial for Janssen's Invokana.

Faster, Better? Fujitsu, Polarisqb 'Quantum-Inspired' Tech Speeds Discovery

Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.

Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

UsernamePublicRestriction

Register

PS113919

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel